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Abstract
BACKGROUND—CYP2C9 and VKORC1 genotypes predict therapeutic warfarin dose at
initiation of therapy; however, the predictive ability of genetic information after a week or longer
is unknown. Experts have hypothesized that genotype becomes irrelevant once International
Normalized Ratio (INR) values are available because INR response reflects warfarin sensitivity.
METHODS—We genotyped the participants in the Prevention of Recurrent Venous
Thromboembolism (PREVENT) trial, who had idiopathic venous thromboemboli and began low-
intensity warfarin (therapeutic INR 1.5-2.0) using a standard dosing protocol. To develop
pharmacogenetic models, we quantified the effect of genotypes, clinical factors, previous doses,
and INR on therapeutic warfarin dose in the 223 PREVENT participants who were randomized to
warfarin and achieved stable therapeutic INRs.
RESULTS—A pharmacogenetic model using data from day 0 (before therapy initiation)
explained 54% of the variability in therapeutic dose (R2). The R2 increased to 68% at day 7, 75%
at day 14, and 77% at day 21, because of increasing contributions from prior doses and INR
response. Although CYP2C9 and VKORC1 genotypes were significant independent predictors of
therapeutic dose at each weekly interval, the magnitude of their predictive ability diminished over
time: partial R2 of genotype was 43% at day 0, 12% at day 7, 4% at day 14, and 1% at day 21.
CONCLUSION—Over the first weeks of warfarin therapy, INR and prior dose become
increasingly predictive of therapeutic dose, and genotype becomes less relevant. However, at day
7, genotype remains clinically relevant, accounting for 12% of therapeutic dose variability.
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Prevention and treatment of venous thromboembolism (VTE) with the oral anticoagulant
warfarin is indicated for a wide variety of patients. Warfarin has a narrow therapeutic
window requiring frequent monitoring of the International Normalized Ratio (INR) until a
stable dose is achieved. Initiation of warfarin poses challenges for both clinicians and
patients due to complex pharmacology, risks of bleeding and clotting, and great inter-subject
dose variability. Typically, clinicians dose warfarin on an empiric basis--using clinical and
demographic factors (e.g. age) to estimate a starting dose and INR response to make
subsequent refinements. Traditionally, this trial-and-error process does not take genotype
into account.
In addition to clinical and demographic factors, genetic variations in two genes affect
patients’ therapeutic warfarin dose. Single nucleotide polymorphisms (SNPs) in the
cytochrome P450 2C9 gene (CYP2C9) affect the rate at which patients metabolize S-
warfarin, the more active enantiomer of the drug. Patients with a CYP2C9*2 and/or
CYP2C9*3 SNP metabolize warfarin more slowly than a wildtype patient (CYPC29*1/*1),
resulting in lower therapeutic warfarin doses.[1] Patients with haplotype A of the vitamin K
epoxide reductase complex 1 (VKORC1) gene have reduced expression of the VKOR
protein and concomitant increased warfarin sensitivity.[2,3] Thus, these common genetic
factors often result in a patient requiring a greater or lesser dose than clinically anticipated.
Clinical dosing algorithms and genetic-based dosing algorithms have been developed to
assist clinicians a priori in estimating a stable warfarin dose. Clinical algorithms account for
about 17-22% (R2)[4] and genetic algorithms account for about half (R2 ~50%) of the dose
variability.[5-8] Genetic-based algorithms that incorporate an INR after 3 or 4 warfarin
doses are even more accurate.[9,10] However, clinical algorithms also become more
accurate after several days of therapy[11,12], prompting some experts to argue that genetic
information becomes irrelevant once INR response is known.[13] This uncertainty is
important because currently clinicians are reluctant to consider obtaining genotype
information if results will not be available within the first few days of warfarin therapy. If
genotype proves to be useful beyond the first few days of therapy, it could be combined with
clinical and demographic factors to create a family of dose-refinement algorithms.
To address these issues, we quantified the ability of CYP2C9*2, CYP2C9*3, and VKORC1
−1639 SNPs to predict therapeutic dose at the time of initiation of warfarin therapy and after
days 7, 14, and 21 of therapy in participants of the PREVENT trial.[14] PREVENT was a
randomized, double-blind, placebo-controlled trial of low-intensity warfarin (therapeutic
INR 1.5-2.0) for the prevention of recurrent VTE that was terminated early after its
independent Data and Safety Monitoring Board found a 64% risk reduction in recurrent
VTE. PREVENT participants had an INR drawn at baseline and then weekly for four weeks,
allowing us to evaluate the relevance of genotype on INR control and final therapeutic dose
in the setting of protocol-driven INR monitoring and standardized dose adjustments.
METHODS
We collected blood, demographic variables, laboratory data, smoking status, and medication
information from participants. The Human Subjects’ Committee approved the research
protocol. All subjects gave written, informed consent.
Study Subjects
The study population consisted of the 508 participants in the PREVENT trial. Eligible
subjects had experienced an idiopathic venous thromboembolic event, completed at least 3
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months of standard anticoagulation therapy (INR 2-3), and returned to a baseline INR <1.2
following discontinuation of standard warfarin therapy. Potential participants were excluded
if they were taking dipyridamole, ticlopidine, clopidogrel, heparin, >325 mg of aspirin, or
drugs that affected the prothrombin time. After their INR had drifted to <1.2 and prior to
randomization to long-term treatment with warfarin or placebo, all participants took part in
an open label 28-day run-in phase to ensure compliance and to determine therapeutic
warfarin dose for an INR target of 1.5-2.0. Starting with an initial dose of 3.0 mg, dose
adjustments were made based on approximately weekly INR determinations using a study-
specific clinical nomogram.[14] Genotyping was performed after the completion of
PREVENT. Our primary analysis of the importance of genetic factors in dose prediction on
days 0-21 was performed using therapeutic doses from the patients randomized to long-term
warfarin (n=223). Our secondary analysis of importance of genetic factors for INR control
was performed based on all patients (n=508) during the 28-day run-in phase.
Genotyping
We extracted DNA from white cell buffy coats (Gentra Systems Puregene kit, Minneapolis,
MN) prepared from a 10-ml EDTA anticoagulated blood sample collected from each
participant during the original PREVENT study. We used Pyrosequencing™ [15,16] to
genotype for four SNPs: CYP2C9*2 [rs1799853], CYP2C9*3 [rs1057910], VKORC1 6853
[rs8050894] and −1639 [rs9923231] (listed with dbSNP reference SNP identifiers).
VKORC1 SNPs −1639 and 6853 are in high linkage disequilibrium and designate haplotype
A, which is associated with increased warfarin sensitivity.[2] PCR reactions and
Pyrosequencing were performed as previously prescribed.[4] The genotyping platforms for
the SNPs of interest are 99-100% accurate.[17]
Clinical and Genetic Variables
We used height and weight to estimate body surface area (BSA).[18] For CYP2C9*2,
CYP2C9*3, and VKORC1 −1639 (A genotype and A haplotype) we coded each of the three
SNPs using its own dummy variable coded as 0, 1, or 2 to quantify the number of variant
alleles. We used dummy variables to code for demographic factors (sex and race), smoking
status, and key medications (amiodarone, statins, aspirin). We defined therapeutic dose as
the dose resulting in two in-range INR values following a week of steady dose regimen. To
get a more accurate estimate of the final therapeutic dose for each patient, we excluded 285
patients from our primary analysis because they were randomized to placebo or failed to
become therapeutic.
Statistical Analyses
In the primary analysis, we used multiple linear regression to test the effect of the genetic
and clinical factors on percent of variability in log-transformed therapeutic dose values at
four times: days 0, 7, 14, and 21 of therapy. We used backward selection to select the
predictor variables and to quantify the corresponding partial R2. For this analysis, we
included only those participants who were randomized to warfarin and achieved a stable
therapeutic INR (n = 223); others were excluded because they lacked long-term follow-up (n
= 261), did not achieve a stable therapeutic dose (n = 11), or were missing clinical or genetic
factors (n = 13). In all four regression models, we adjusted for clinical factors, and starting at
day 7, we also adjusted for the prior week’s average dose and most recent INR value. We
then repeated the analysis in 250 bootstrapped samples to obtain the standard deviations for
the R2 values.
In the secondary analyses, we used logistic and linear regression to determine the
association between VKORC1 A haplotype (−1639 A genotype), CYPC29 genotype, and
clinical variables with time above and then with time below the target INR range (1.5–2.0).
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For these analyses, we used INR data from all participants during the 28-day run-in phase.
We calculated percent time each patient spent above and below therapeutic INR range
between days 7 to 28 using linear interpolation.[19] The percentage of subtherapeutic time
was normally distributed and was modeled by linear regression. In contrast, because most
patients were never above the target INR range (“supratherapeutic”), that distribution was
not normally distributed. We therefore modeled supratherapeutic time separately, using a
two-staged approach: (1) we used logistic regression to compare subjects who did and did
not have INR values above 2.0, then (2) in a subgroup analysis of subjects who had at least
one above-range INR value we analyzed factors affecting the time spent supratherapeutic.
We used backward selection to select the predictor variables. Variables with p-values <0.10
were retained in the models if they were biologically plausible, but only variables with p-
values <0.05 were considered statistically significant. By examining residual errors, we
confirmed the appropriateness of the linear regression models. We performed statistical
analyses in SAS (Version 9.1; SAS Institute, Inc; Cary, NC).
RESULTS
After excluding 13 subjects with missing clinical or genetic information, the sample
consisted of 495 participants. Mean age was 55 (range 30 – 89), 88% were Caucasian, and
47% were female (Table 1).
Effect of Genetic, Clinical, and Laboratory Factors on Therapeutic Dose after 0-21 Days of
Therapy
As dosing history and INR response became more extensive over the initial 3 weeks of
therapy, the model progressively explained more of the variance in therapeutic dose by
accounting for this information. The overall R2 increased weekly (Figure 1): 54% at day 0;
68% at day 7; 75% at day 14; and 77% at day 21. Although genetic factors (VKORC1 A
haplotype, CYP2C9*2, and CYP2C9*3) were significant in all models, their contribution to
explaining the therapeutic dose (partial R2) declined steadily: 43% at day 0; 12% at day 7;
3.9% at day 14; and 1.4% at day 21. The contribution of INR to partial R2 also declined over
time: 32% at day 7, 19% at day 14, and 5% at day 21 (Table 2). In contrast, the dosing
history became progressively more predictive of therapeutic dose, easily trumping other
factors over time: partial R2 18% at day 7; 50% at day 14; and 69% at day 21 (Figure 1).
Time Spent Below and Above Therapeutic Range: Days 7-28
In the regression analysis, both VKORC1 and CYP2C9 genotypes had significant effect on
time spent below therapeutic range. Time spent below therapeutic range decreased by 16%
per VKORC1 A haplotype and 11% per CYP2C9 variant allele. The variables that increased
time spent below therapeutic range were younger age (3.6% per decade, p<0.0001) and
greater body surface area (3.1% per standard deviation, p=0.04). Female gender had a
borderline effect (5.7% less time than in males, p=0.054). Thirty-nine percent of subjects
had at least one INR above 2 during days 7-28. In the logistic regression, both VKORC1 and
CYP2C9 genotypes influenced the odds of supratherapeutic dosing. The odds ratios (OR)
for over-anticoagulation were 2.6 (95% confidence interval [CI] 1.9-3.5) per A haplotype of
VKORC1 and 2.9 (95% CI 2.0-4.2) per CYP2C9 variant allele. The odds of over-
anticoagulation also significantly increased with increasing age (OR=1.4, 95% CI 1.2-1.7
per decade, p<0.0001). Among patients with at least one supratherapeutic INR, patients with
CYP2C9 variants and VKORC1 A allele spent significantly more time in the
supratherapeutic range. (Effect per allele/haplotype: 5.8% and 5.6% absolute increase in
supratherapeutic time for CYP2C9 and VKORC1, respectively). Older age was associated
with increased supratherapeutic time (4.0% per decade, p=0.0003).
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This study quantifies the decreasing predictive ability of CYP2C9 and VKORC1 genotype
during the initial weeks of warfarin therapy. While the overall accuracy of the
pharmacogenetic model improved over time, the incremental benefit of knowing a patient’s
genotype decreased over time (Figure 1).
While some experts argue that pharmacogenetic information has a promising future for
patients on warfarin[20,21], others argue that genetic information adds little incremental
information once INR response is available.[22-25] Our observations suggest that both
opinions may be valid. On the one hand, we found that after 7 days of warfarin, CYP2C9
and VKORC1 still account for substantial (12%) variability in therapeutic dose. Although
genotype is more predictive before initiation (43%), the increased predictive ability it adds
after 7 days could help clinically. In particular, some outpatients do not have their INRs
checked until a week after therapy begins[26,27], so improving the accuracy of dose
refinements made after 7 days might prevent adverse events. Without genetic dosing, the
rate of hemorrhage is highest during the initial weeks of therapy, so pharmacogenetic dose
adjustments at this time might prevent hemorrhages. In a trial of Israeli patients beginning
warfarin, 95 patients randomized to pharmacogenetic dosing for the first 8 days of therapy
had fewer minor hemorrhages than the 96 patients dosed using a clinical algorithm[21], but
other trials of pharmacogenetic dosing have not prevented hemorrhages.[28,29]
On the other hand, we found that as INR results become available during the first weeks of
therapy, genetic information provides a lower degree of predictive ability. For example, the
INR during the first week of therapy will often be elevated in a patient who is VKORC1
sensitive, but dose adjustments will compensate for this effect over the subsequent weeks.
[30] Here we find that after 3 weeks, the dose history trumps the value of information
contained in genotype.
The results of our secondary analyses suggest that genetic information might be helpful after
initiation of warfarin. When using INR data from days 7-28, CYP2C9 and VKORC1
genotypes were significant predictors of the amount of time patients spent below therapeutic
range and the odds of having a supratherapeutic INR. These results suggest that weekly
monitoring (as mandated in PREVENT) does not completely compensate for the presence of
genetic SNPs for several weeks. This is likely because the INRs at days 7 and 14 have not
yet captured the entire genetic effects. The effect of CYP2C9, in particular, may elevate the
INR after the initial week of therapy [30] and not be fully reflected in the initial INR
response. Because supratherapeutic INRs are associated with major hemorrhage[31],
patients with VKORC1 and/or CYP2C9 variants have triple the risk of adverse events
during the initial weeks of therapy.[1,32,33] This observation, along with our finding that
genotype improved R2 by 12% at day 7 of therapy, suggests that additional research is
needed to delineate the safety and effectiveness of pharmacogenetic-guided dosing that
extends past the first few days of therapy.[9,10] In particular, multi-centered randomized
trials should test the hypothesis that pharmacogenetic dosing improves laboratory and
clinical outcomes over the initial weeks of therapy.
A few limitations of our study merit consideration. PREVENT participants had a low target
INR (1.5–2.0), which proved effective at preventing recurrent VTE.[14] Although we did
not observe an interaction between predictive ability of genotype and target INR in our prior
analysis[4], the predictive ability of genotype also might vary with dosing practices and INR
monitoring. A second potential limitation is that our models were developed using INR
values that were obtained only once weekly. The degree that genotype correlates with dose
after 1, 2, or 3 weeks of therapy may be diminished in populations who monitor their INR
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more frequently. A third potential limitation is the consistent indication for warfarin among
patients in the PREVENT trial, as all patients were taking warfarin for prevention of
recurrent VTE. While this consistency eliminates potential confounding by indication, it
limits generalizability to other diseases. Because of these limitations and lack of a validation
cohort, we did not develop a dose refinement algorithm for clinical use. In the future, we
hope to combine the PREVENT data with data from diverse populations to develop such an
algorithm.
The limitations are balanced by several strengths. One strength is that we assured accurate
therapeutic dose determination by requiring two consecutive therapeutic INRs. A second
strength is that PREVENT used a standard initial dose and dose adjustment protocol, thus
preventing inter-clinician variability in prescribed dose. A final strength is that all
participants were followed prospectively as part of a multi-centered randomized trial.
In summary, we found that SNPs causing slower warfarin metabolism and increased
warfarin sensitivity account for significant variability of therapeutic warfarin dose. These
SNPs are associated with increased risk of supratherapeutic INRs up to 28 days after
initiation. However, the importance of genotype wanes over the initial weeks of therapy.
Our findings should prompt future studies to develop and assess the clinical utility of a day 7
pharmacogenetic dosing algorithm.
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Percentage of dose variation explained at weekly time points.
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Table 1
Demographic, Genetic, and Clinical Characteristics of Participants
DEMOGRAPHIC VARIABLES N = 495
 Age, mean (SD), years 55 (13)
 Gender
  female, n (%) 234 (47%)
  male, n (%) 261 (53%)
 Race
  Caucasian, n (%) 434 (88%)
  African-American, n (%) 47 (9%)
  Other, n (%) 14 (3%)
 Hispanic ethnicity, n (%) 6 (1%)
GENETIC VARIABLES




 CYP2C9*2 allele frequency 12.2%
 CYP2C9*3 allele frequency 6.4%
CLINICAL VARIABLES
 geometric mean warfarin dose,
 mg/day, (SD)
4.4 (1.5)
 body surface area, in m2 mean (SD) 2.05 (0.27)
 smoker, n (%) 57 (12%)
 takes statin, n (%) 53 (11%)
 takes amiodarone, n (%) 0 (0%)
 takes aspirin, n (%) 97 (20%)
SD = standard deviation; VKORC1 = vitamin K epoxide reductase complex 1. CYP = cytochrome P 450.
a
The VKORC1 A haplotype can be detected by −1639 G>A;
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Table 2
Percent of Dose Variation Explained (partial R2) at Weekly Timepoints
Day 0 Day 7 Day 14 Day 21
Genetic 42.8% 12.1% 3.9% 1.4%
Clinical 10.8% 6.4% 2.2% 1.9%
INR 0% 31.7% 19.1% 5.1%
Prior Dose 0% 18.0% 50.3% 68.6%
TOTAL 53.6% 68.1% 75.4% 77.0%
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